Hepion reports $71.7M cash; progressing Phase 2 NASH and upcoming HCC trials

Hepion Pharmaceuticals, Inc.

Cash and equivalents of $71.7M as of June 30, 2022; 76.2M common shares outstanding.
Rencofilstat Phase 2b ASCEND-NASH (biopsy) and Phase 2 ALTITUDE-NASH (liver function) trials underway.
Upcoming Phase 2a HCC trial for rencofilstat in advanced hepatocellular carcinoma.
AI-POWR platform used to identify responders and companion diagnostic panel.
Rencofilstat shown safe/tolerated in >200 subjects; Phase 2a AMBITION study met primary endpoints.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.